# A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

> **NCT02703272** · PHASE3 · TERMINATED · sponsor: **Janssen Research & Development, LLC** · enrollment: 72 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** Ibrutinib
- **DRUG:** Rituximab
- **DRUG:** Ifosfamide
- **DRUG:** Carboplatin
- **DRUG:** Etoposide
- **DRUG:** Vincristine
- **DRUG:** Idarubicin
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02703272
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-07-01
- **Primary completion:** 2021-06-11
- **Final completion:** 2021-06-11
- **Target enrollment:** 72 (ACTUAL)
- **Why stopped:** IDMC recommended that enrolment be stoped, as the EFS hazard ratio and associated p-value crossed the futility boundary specified in protocol (July 2020).
- **Last updated:** 2022-12-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02703272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02703272, "A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02703272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*